What China Will Do With U.S. Trade Talks?
The standstill between the U.S. and China showed signs of easing. China said on May 2 that it is assessing U.S. proposals for tariff negotiations. However, China also wanted the White House to show sincerity.China sent delegates to the U.S. They have headwinds of a 145% tariff on imported Chinese goods to start with. China responded by imposing retaliatory tariffs at 125%. Since then, Chinese ETFs like KWEB, ASHR, and FXP performed well. China’s offshore yuan also strengthened, holding the 7.3 level against the U.S. dollar (DXY).U.S. ManufacturingThe U.S. has too much debt. The cost of servicing it is unsustainable. The country needs to rebuild its manufacturing capacity to change its path. Even though the stock markets want the trade war to end, a quick resolution is not likely.China quietly exempted many U.S.-made goods from its 125% tariffs last week. According to Bloomberg, China applied the exemption on goods worth around $40 billion in imports. This would alleviate the impact of the trade war on the Chinese economy. The list included U.S. products of pharmaceuticals and industrial chemicals.Specialty chemical firms like Chemours (CC) and LyondellBasell (LYB) bounced back. Drug firms like Merck (MRK), Pfizer (PFE), and Bristol-Myers (BMY) also recovered on the stock markets recently.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


